[Precursors of acute leukemia: myelodysplastic syndromes and myeloproliferative neoplasms].
Myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) represent neoplastic proliferations of hematopoietic stem cells, which may progress to loss of differentiation and acute myeloid leukemia (AML). Transitions between MDSs and MPNs as well as combinations between both disorders occur and MPNs may acquire dysplastic features combined with cytopenia. Myelodysplastic/myeloproliferative neoplasms show dysplastic and myeloproliferative properties and have in common genetic aberrations at the stem cell level (TET2, ASXL 1, CBL, IDH 1, IDH 2, EZH2, p53, Runx1), which may be found in one cell or may affect different hematopoietic stem cells, expanding in parallel. Progress to AML follows a linear clonal evolution only in a subset of cases. Alternatively AML derives from secondary clones, devoid of any marker mutation or originates from a common aberrant progenitor cell which shares other but not the JAK2                         (                            V617F                         ) mutation.
Institut für Pathologie, Medizinische Hochschule Hannover, Carl Neuberg Str. 1, 30625, Hannover, Deutschland. Kreipe.Hans@MH-Hannover.de
H H
HH
Kreipe
D000208:Acute Disease; D049109:Cell Proliferation; D002471:Cell Transformation, Neoplastic / Q000235:genetics* / Q000473:pathology*; D002869:Chromosome Aberrations; D004252:DNA Mutational Analysis; D006412:Hematopoietic Stem Cells / Q000473:pathology; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000473:pathology*; D009190:Myelodysplastic Syndromes / Q000235:genetics* / Q000473:pathology*; D009196:Myeloproliferative Disorders / Q000235:genetics* / Q000473:pathology*; D011087:Polycythemia Vera / Q000235:genetics / Q000473:pathology; D011230:Precancerous Conditions / Q000235:genetics* / Q000473:pathology*
C507924:JAK2 protein, human; D053614:Janus Kinase 2